echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 6 billion market epilepsy drug Enhua Pharmaceuticals overrated Haizheng over 1 billion grade products first

    6 billion market epilepsy drug Enhua Pharmaceuticals overrated Haizheng over 1 billion grade products first

    • Last Update: 2020-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    TextsAs of now, CDE cumulative acceptance of 2062 consistency evaluation acceptance number (545 enterprises of 501 varieties, according to supplementary applications, the same below);This week (May 15 to May 22) there are four more varieties through the consistency evaluation, Zhejiang Haizheng Pharmaceuticals added the first over-rated varieties, for the McCorcorthol capsulesthis week's consistency evaluation of the details of the table
    Ibuprofen tablets are over-the-counter drugs for heat relief analgesics, and are medically covered drugs, used to relieve light to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, nerve pain, pain, but also for common cold or influenza-induced feverIbuprofen is a children's anti-fever drug recommended by the World Health Organization and the U.SFDAaccording to theAccording to the data, there are 427 batch of ibuprofen tablets in the domestic market, involving 307 enterprises, in 2019 ibuprofen tablets domestic sample hospital sales of 1578 million yuan, the highest proportion is Henan Quanyu Pharmaceutical 36.9%, followed by Henan Tianfang Pharmaceuticals (17.52%), Shandong Xinhua Pharmaceuticals (10.72%)so far a total of 6 enterprises to declare ibuprofen tablet consistency evaluation, Xinhua Pharmaceuticals this week is the second after the stone medicine European Italy through the lofin tablet consistency evaluation, it is worth mentioning that its specifications of 0.2g is the first domestic evaluationDemccophenolisis is a low-toxic immunosuppressant that is suitable for preventing rejection and treatment of refractory rejection in patients with the same type of kidney transplant, and can be applied simultaneously with cyclosporine and adrenal corticosteroidsIs it for McCorvey ester capsule original research enterprise for Roche, according to pharmacological data, there is currently for McCorveheol capsules domestic market approval 11, manufacturers 11according to, the global sales of McCorcorthin capsules in 2019 were about $371.9964 million, of which China sales were about $12.4817millionAccording to the data of medicine, up to now, only Hangzhou Central and American East China Pharmaceuticals, Zhejiang Haizheng Pharmaceuticals, Yan Tianyin Pharmaceuticals three enterprises this variety consistency evaluation was accepted, of which Zhejiang Haizheng Pharmaceutical scored the first evaluation; The following table:Zhejiang Haizheng Pharmaceutical Conformity Evaluation Details Table
    Amoxicillin belongs to penicillin-type broad-spectrum beta-lactam antibiotics, for most of the disease-causing Gram-positive bacteria and Gram-negative bacteria have a strong antiseptic and sterilization effect It is reported that in 2019 Amoxelin capsule domestic sales of about 2.4 billion yuan, up 10% year-on-year According to the data, Amoxicillin capsules for consistency evaluation of popular varieties, 38 enterprises declared to be accepted, of which 16 enterprises three different specifications (0.25g, 0.125g, 0.5g) have been evaluated, located in the top three of the number of enterprises rated varieties The Gabba spray capsule is used to treat the after-effects nerve pain of shingles and to assist in the treatment of local seizure epilepsy The Gabba capsule was developed by Warner-Lamber corporation of the United States, which was first approved for listing in the United Kingdom on May 10, 1993, was approved by the FDA in the United States in December of that year, and was acquired by Pfizer Corporation in 2000 According to IQVIA, the total global sales of the Gaba-Ding capsules in 2019 were about $831.45 million, with domestic sales of about $16.1 million According to the data, the Gabba capsule is currently only Enhua Pharmaceuticals and Hengrui Pharmaceuticals two enterprises have market approval, and both enterprises are now through a consistent evaluation, will jointly step by deer 6 billion epilepsy drug market This week CDE new consistency evaluation acceptance number 14 (11 varieties), 4 varieties for the new drugs, respectively, Yichang Renfu Pharmaceutical's fluorasine injection and liponate metorol injection, Hubei Shubang Pharmaceutical's Nimmy Shuli dispersion tablets and Zhuhai Rundu Pharmaceutical's Ebeshatan capsule details of the acceptance of this week's consistent evaluation declaration It is worth mentioning that last week the State Drug Administration issued a request for injection consistency evaluation work officially launched, this week, the two injections of human medicine have been accepted, flumasini injections, circnate metorol injections have been included in the shortage of drugs listed by several provinces According to the data of medicine, so far, there are 40 consistency evaluation acceptance numbers in the human medicine industry, of which 24 are injections, and the top 10 enterprises are declared for the consistency evaluation of injections
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.